(FATE) Fate Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(FATE) Fate Therapeutics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Fate Therapeutics, Inc. BCG Matrix helps you evaluate the company’s portfolio across Stars, Cash Cows, Question Marks, and Dogs for strategy, research, and capital allocation. The page already shows a real preview of the analysis, so you can see the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
FT819 lead iPSC-derived CAR T
FT819 is a clinical-stage, off-the-shelf iPSC-derived CAR T asset for hematologic cancers and solid tumors, so it fits the "Star" bucket if trial data keep improving. Its value at end-2025 depends on pipeline progress, because it still has no product revenue. In a cell-therapy market that rewards scale and consistent manufacturing, differentiated process control can be a real edge.
FT596 iPSC-derived CAR NK
FT596 iPSC-derived CAR NK is a clinical-stage NK-cell program for B-cell lymphoma and chronic lymphocytic leukemia, two large oncology markets with clear unmet need. Its Star status depends on stronger 2025–2026 readouts, since clinical data will drive adoption and pipeline value. For Fate Therapeutics, this asset can be a high-growth platform if efficacy and durability hold up.
Ono 2-asset CAR T collaboration
Fate Therapeutics’ Ono collaboration covers 2 off-the-shelf iPSC-derived CAR T therapies, giving the company external validation plus non-dilutive development support. The deal helps de-risk one of Fate’s highest-potential assets, since partner funding can offset R&D burn while the platform advances. At end-2025, this looks like one of Fate’s strongest Stars in the BCG mix.
Juno small-molecule modulator collaboration
The Juno small-molecule modulator collaboration is a high-value R&D tie-up for genetically engineered T-cell therapies, not a sales line. It supports Fate Therapeutics, Inc.’s broader cell-therapy platform and fits a BCG matrix role of strategic technology support with 0 direct commercial revenue. This is more about pipeline depth and partnering leverage than product cash flow.
- Platform support, not product sales
- Targets engineered T-cell immunotherapies
- High strategic value, low current revenue
Janssen option agreement
Janssen option agreement is a Star in Fate Therapeutics, Inc.’s BCG view because it links Fate’s induced pluripotent stem cell platform to a major pharma partner. The deal gave Johnson & Johnson’s Janssen an option on select programs, with Fate’s 2020 collaboration headlines citing up to $3.1 billion in total milestones and royalties.
That structure creates real partnering optionality in a fast-growing immunotherapy market, where global cell-therapy sales are still early but expanding quickly. It can turn platform science into future development economics, not just research output.
- Partnered platform with option value
- Upside from milestones and royalties
- Strategic in immunotherapy growth
Fate’s FT819 and FT596: Big Market Upside Hinges on 2025-26 Data
FT819 and FT596 are Fate Therapeutics, Inc. Stars because they sit in large oncology markets and still have high upside if 2025–2026 data improve. The Janssen option deal adds strategic value, with up to $3.1 billion in milestones and royalties, plus partner validation for the iPSC platform. These assets still have no product revenue, so trial execution drives the BCG case.
What is included in the product
Detailed Word Document
Fate Therapeutics’ BCG Matrix maps its cell-therapy portfolio to show where to invest, hold, or cut.
Editable Excel File
Quick BCG view of Fate Therapeutics, Inc. to spot each segment fast and ease strategy decisions.
Reference Sources
Provides a clear source trail for Fate Therapeutics, Inc. to verify key claims, strengthen credibility, and support faster investment decisions.
Cash Cows
0 approved products
As of end-2025, Fate Therapeutics, Inc. had 0 approved products and no marketed drugs, so it did not have a mature product line generating steady product cash. Its 2025 revenue was still tied to collaboration and other non-product sources, not sales of an approved therapy. So, Fate Therapeutics, Inc. is not a classic cash-cow business.
0 product sales
In 2025, Fate Therapeutics reported no product sales, so the Cash Cows bucket was empty. Cash generation did not come from a mature brand portfolio, which means operations could not fund growth on their own.
This weakens internal funding power and leaves the Company more reliant on external capital. For a BCG matrix, that is a clear sign of a non-cash-cow business with no stable sales base.
Collaboration revenue stream
Fate Therapeutics, Inc.'s collaboration revenue is the closest thing to recurring cash inflow, with partner funding helping offset R&D burn before any product sales. In its latest filings, this stream is still small versus costs, but it can extend runway and support programs without new equity. So it fits a weak Cash Cow profile: useful, but not yet a true core cash engine.
Cash and marketable securities
Fate Therapeutics, Inc.’s cash and marketable securities are its main liquidity buffer, not a product-based "cash cow". In a clinical-stage biotech, that balance sheet cash funds R&D, trials, and overhead, so it acts as operating support; in the latest filed period, this reserve was still a key runway driver.
- Liquidity funds clinical development
- Supports burn, not product profits
- Extends runway for trials
Low commercial overhead
Fate Therapeutics, Inc. keeps commercial overhead low because it has no sales force, no marketed inventory, and no launch spend to carry. That preserves cash better than a launched biotech, but it also means there is no approved product to harvest for profit. In BCG terms, this is a cash-preservation play, not a cash cow.
- No sales force
- No marketed inventory
- Low launch costs
- No product cash milk
Fate Therapeutics Had No Cash Cow in 2025
Fate Therapeutics, Inc. had no approved products and no product sales in 2025, so it had no true Cash Cow. Its closest cash source was collaboration revenue, but that only offset R&D burn, not generate durable product profit.
| Metric | 2025 |
|---|---|
| Approved products | 0 |
| Product sales | $0 |
| Cash source | Collaboration revenue |
What You See Is What You Get
Fate Therapeutics, Inc. Reference Sources
You're previewing the exact Fate Therapeutics, Inc. BCG Matrix report you'll receive after purchase. What you see here is the final, fully formatted document—no demo pages, no placeholders, no watermarks. Once purchased, the same file is delivered instantly for your use in strategy reviews, presentations, or analysis.
Dogs
No marketed franchise
There was no approved product franchise at end-2025, so Fate Therapeutics, Inc. had $0 commercial product sales and no low-growth legacy brand to harvest. In BCG terms, classic "dogs" are largely absent; the portfolio stayed pre-commercial and depended on cash and collaborations, not mature products.
No royalty-heavy mature asset
Fate Therapeutics had no mature royalty stream from a commercial product in FY2025, so this "dog" label does not fit the usual low-share, low-growth pattern. The value is still tied to pipeline assets, not a cash royalty base. With no marketed product royalties, any upside depends on clinical progress and capital use.
No stable product revenue base
Fate Therapeutics had no stable product revenue base in FY2025, with net product sales at $0 because it had no approved commercial drug. Revenue came from research collaborations and milestones, not a durable brand, so there was no mature line to divest or harvest. The portfolio stayed precommercial, which is why the BCG "Dog" label fits.
High R and D burn
Fate Therapeutics is still in the high-burn phase: as a clinical-stage cell therapy Company, it spends heavily on R&D before any product revenue can arrive. That makes the dog risk clear, because stalled programs can tie up cash for years and force more dilution or cuts.
- High R&D spend, delayed payoff.
- Stalled programs can trap cash.
- Ongoing losses raise dilution risk.
Programs without late-stage proof
Fate Therapeutics had zero late-stage, registrational programs in its recent pipeline, so these assets still have low share and little near-term traction. Without phase 2/3 human proof, they can stay stranded if data do not improve, which is the classic biotech dog outcome. That also leaves the Company with weak revenue pull and high cash-burn risk.
- Zero late-stage proof
- Low near-term commercial traction
- High risk of being stranded
Dogs Are Scarce: Fate Stayed Pre-Commercial in FY2025
Dogs are limited in Fate Therapeutics, Inc. because FY2025 had $0 product sales and no approved commercial drug, so there was no mature low-share brand to harvest. The portfolio stayed pre-commercial, with revenue tied to research collaborations and milestones, not a stable product base. High R&D burn and no late-stage registrational program keep dilution and cash-trap risk high.
| FY2025 | Value |
|---|---|
| Product sales | $0 |
| Approved products | 0 |
| Late-stage registrational programs | 0 |
Question Marks
FT500 advanced solid tumors
FT500 targets advanced solid tumors in a large, fast-growing oncology market, where solid tumors account for about 90% of all cancers. It is an off-the-shelf cell therapy, but its market share is still near zero because it remains clinical-stage and has not yet generated commercial sales. The key test is efficacy data; without clear response rates and durable benefit, FT500 risks staying a Question Mark and slipping toward Dog status.
FT516 AML, B-cell lymphoma, solid tumors
FT516 sits in multiple large oncology markets, including AML, B-cell lymphoma, and solid tumors, but its commercial share is still zero because it has no approved indication. AML alone is about 20,800 new U.S. cases a year, and non-Hodgkin lymphoma is about 80,620, so the upside is real if data holds. Clinical uptake will hinge on safety and response depth, since buyers need clear proof of benefit before moving from trial use to routine care.
FT538 AML and multiple myeloma
FT538 AML and multiple myeloma sits in two fast-growing hematologic cancer markets, but it is still a question mark because commercial proof is limited. Acute myeloid leukemia had about 20,800 new U.S. cases in 2024, and multiple myeloma about 35,000, yet FT538 still needs stronger efficacy, safety, and partnering data to convert growth into share.
That means more capital and late-stage evidence are needed before it can move toward a star.
FT576 multiple myeloma
FT576 for multiple myeloma sits in a large oncology arena where new cell therapies still draw strong demand, especially after CAR-T and bispecific data reset treatment benchmarks. As of FY2025, its market share is effectively nil because Fate Therapeutics, Inc. has not commercialized the program, so there is no product revenue to show. That makes FT576 a classic invest-or-exit question mark: high upside if clinical data de-risk it, but no current cash flow to support the case.
- Major myeloma market, high innovation pull
- FY2025 share: effectively nil
- No marketed sales, no revenue contribution
- Pure question mark: fund or exit
FT536 solid tumors
FT536 remains a Question Mark: it targets solid tumors, one of the largest oncology markets, but it is still a development-stage asset with no product revenue. Its upside is real if later clinical data show better response rates and durability, since solid-tumor wins can re-rate a pipeline fast. If the data stay weak, it likely keeps consuming cash without shifting Fate Therapeutics, Inc.'s BCG mix.
- No approved revenue yet
- Big market, high upside
- Clinical traction is the key
- Weak data means cash burn
Fate’s Pipeline Is Big Market, Zero Share—Clinical Proof Will Decide
Fate Therapeutics, Inc.’s Question Marks are FT500, FT516, FT538, FT576, and FT536: all sit in large oncology markets, but FY2025 commercial share is still effectively zero because none is approved. AML had about 20,800 U.S. cases in 2024, multiple myeloma about 35,000, and non-Hodgkin lymphoma about 80,620. Their BCG status depends on clinical proof, not demand.
| Program | Market | FY2025 share | BCG read |
|---|---|---|---|
| FT500 | Solid tumors | 0 | Question Mark |
| FT516 | AML/lymphoma | 0 | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.